DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
CENTER FOR DRUG EVALUATION AND RESEARCH

Office of Manufacturing and Product Quality
Division International Drug Quality
International Compliance Branch
10903 New Hampshire Avenue
Building #51, Room 4212
Silver Spring, MD 20993

TELEPHONE: (301) 796-3916
FAX: (301) 847-8742

December 3, 2014

Mr. Billent Atabay
Owner and President
Atabay Kimya Sanayi Ve Ticaret A.S.
34718 Kadikoy
Acibadem, Koftuncu Sokak No. 1
Istanbul, Turkey 34718

Reference: FEI 3002806424

Dear Mr. Atabay:

We have completed our review of the Establishment Inspection Report (EIR) for the inspection conducted at your Active Pharmaceutical Ingredient (API) manufacturing facility in Instanbul, Turkey by Investigator Isabel Espinosa during the period of March 31, 2014 to April 4, 2014.

Based on the profile class covered during the inspection, we are classifying your facility as acceptable. This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to assure continued compliance with current good manufacturing practices (CGMPs).

Please be advised that all manufacturers must register annually as required by 21 C.F.R. § 207.40. Information on how to register is available at http://www.fda.gov/cder/drls/registration_listing.htm.

Additionally, we enclose a copy of the establishment inspection report (EIR). Releasing this EIR to you is part of FDA's effort to make its regulatory process and activities more transparent to the regulated industry. It is being provided to you for information purposes only and may reflect some redactions made by the Agency in accordance with the Freedom of Information Act and 21 C.F.R. Part 20. Copies provided to other requestors may have additional redactions of trade secret and confidential commercial information.

If you have any questions regarding this letter, you may contact me at the above address or number.

Sincerely,

Maan Abduldayem
Branch Chief (Acting)
Division of International Drug Quality

Enclosure: EIR